Geoffrey Barnes, MD, MSc
gbarnesmd.bsky.social
Geoffrey Barnes, MD, MSc
@gbarnesmd.bsky.social
Vascular Cardiologist at Univ of Michigan Frankel Cardiovascular Center
#thrombosis, #CVcoag, #ImpSci
Co-director of MAQI2 and MPrOVE
Board of Directors and President-elect of the Anticoagulation Forum
🏳️‍🌈
Connie Hess reminds #AHA25 attendees that patients with PAD are at risk for both MACE and MALE. But the specific risk factors and risk spectrum differ for those two adverse outcomes.
November 10, 2025 at 2:36 PM
Here are a few examples of #AntithromboticStewardship interventions. #AHA25
November 10, 2025 at 2:22 PM
Why do clinicians “underdose” DOAC therapy? Sara Vasquez teaches us that there are 3 main drivers! How to address these? #AntithromboticStewardship
November 10, 2025 at 2:19 PM
Akhi Sista nicely compares and contrasts the purpose of the 4 ongoing RCTs in acute PE interventions. #TheVEINS25
November 2, 2025 at 10:42 PM
According to Aditya Sharma, Virchow’a Triad is “out” and the Quartet of Thrombosis is “in”! Now we need to figure out how to target the underlying inflammation that contributes to VTE risk and recurrence risk.

#TheVEINS25
November 2, 2025 at 5:37 PM
A beautiful fall morning!
October 28, 2025 at 11:42 AM
There are so many unanswered questions in acute PE management. Thankfully, we’re finally getting some RCTs to help answer them! #PERT2025
September 17, 2025 at 9:18 PM
Many people wonder if the severity of an acute PE influences VTE recurrence risk and therefore should impact DOAC dose selection? A post-hoc analysis of RENOVE study shows similar rates or recurrent VTE based on PE severity. #ISTH2025
June 25, 2025 at 2:55 PM
Factor XI inhibition is a promising target for preventing thrombosis with a low rate of bleeding. Currently phase 3 trials use small molecule inhibitors or monoclonal antibodies. SRSD107 is an siRNA agent that prevents FXI production. Is 2x-yearly treatment for thrombosis on the horizon? #ISTH2025
June 25, 2025 at 2:40 PM
The cumulative incidence curve for VTE recurrence and bleeding was similar for full dose and reduce dose DOAC in thrombophilia-VTE. #ISTH2025
June 25, 2025 at 2:27 PM
Of the patients who received reduce-dose DOAC, rate of recurrent VTE was reassuringly low! #ISTH2025
June 25, 2025 at 2:25 PM
This prospective study explored the important question of DOAC dose in 200 consecutive patients with thrombophilia and VTE. A little over 2 years of follow up! #ISTH2025
June 25, 2025 at 2:22 PM
I often get asked if DOAC therapy is safe for patients with thrombophilia. We know that standard dose DOAC works well. But what about reduced DOAC dose after the initial 3-6 months of VTE treatment? #ISTH2025
June 25, 2025 at 2:20 PM
Networking event at #ISTH2025… always a blast!! Don’t miss the next on in Paris 2026
June 25, 2025 at 2:16 AM
MAQI2 data presented at #ISTH2025 shows significant cost reductions for warfarin patients in whom unnecessary aspirin was stopped. This supports the financial benefits of a key #AntithromboticStewardship intervention.
June 24, 2025 at 2:12 PM
Patients with mechanical aortic valve replacement undergoing GI endoscopy had more bleeding but similarly low TE rate with LMWH bridging during a warfarin interruption period. #ISTH2025
June 23, 2025 at 2:08 PM
#AntithromboticStewardship can have BIG impact in the long-term care and rehab setting, but often with unique needs! #ISTH2025
June 23, 2025 at 1:05 PM
One Canadian team has audited their inpatient #AntithromboticStewardship efforts. About half of screened patients needed an intervention. And the impact has been sustained over many years! #ISTH2025
June 23, 2025 at 1:04 PM
Are you thinking of starting an #AntithromboticStewardship program? Look to your antimicrobial stewardship programs for guidance/mentorship as they have a wealth of experience to share! You may even convince one of their team members to join yours :) #ISTH2025
June 23, 2025 at 12:59 PM
What’s in a name? As we transition from Anticoagulation Stewardship to #AntithromboticStewardship in order to acknowledge the broader set of activities that improve patient outcomes, these two names will likely be used interchangeably. #ISTH2025
June 23, 2025 at 12:54 PM
Dr Tafur highlights the four domains of a Key Performance Indices scorecard. This framework is helpful for evaluating and communicating the benefit of any system-level #AntithromboticStewardship effort #ISTH2025
June 23, 2025 at 12:44 PM
Dr Tafur demonstrates an example of peri operative #AntithromboticStewardship by providing an electronic alert that automatically calculates the Caprini VTE risk score and pre-selects the option to open a prophylaxis orderset when appropriate (a behavioral nudge). #ISTH2025
June 23, 2025 at 12:34 PM
Pharmacists can serve as the lynch pin of an #AntithromboticStewardship program given their expertise and ability to coordinate care oversight for large groups of patients. #ISTH2025
June 23, 2025 at 12:18 PM
National coordination of #AntithromboticStewardship programs is a critical step for improving public health outcomes! #ISTH2025
June 23, 2025 at 12:15 PM
Hospital stewardship programs that provide education, medication review, guidelines/protocols, and facilitate transitions of care can improve outcomes AND reduce costs! #ISTH2025
June 23, 2025 at 12:10 PM